AQR Capital Management’s Actuate Therapeutics ACTU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-127,493
Closed -$195K – 4160
2026
Q2
$195K Buy
127,493
+100,384
+370% +$233K ﹤0.01% 3805
2026
Q1
$74.3K Buy
+27,109
New +$112K ﹤0.01% 3699

Other funds holding ACTU

AQR Capital Management's ACTU Position: Q3 2026 in Review

AQR Capital Management sold out of Actuate Therapeutics (ACTU) in Q3 2026, closing a stake of 127,493 shares — an estimated $195K sold.

AQR Capital Management first reported a position in ACTU in Q1 2026 and held it in 2 quarters. The position peaked at $195K in Q2 2026. 40 funds tracked by Wall St. Rank hold ACTU as of Q3 2026.

  • AQR Capital Management reported no remaining Actuate Therapeutics position as of Q3 2026 after selling out during the quarter.
  • AQR Capital Management sold 127,493 Actuate Therapeutics shares in Q3 2026, an estimated $195K.
  • AQR Capital Management first reported a position in Actuate Therapeutics in Q1 2026 and held it in 2 quarters.
  • AQR Capital Management's Actuate Therapeutics position peaked at $195K in Q2 2026.
  • 40 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q3 2026.

Based on AQR Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.